An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Romyelocel-L (Primary) ; Filgrastim
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Cellerant Therapeutics
- 15 Nov 2017 Status changed from recruiting to completed.
- 23 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
- 23 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.